Wolfe Research Upgrades Kymera Therapeutics to Outperform

Benzinga Newsdesk www.benzinga.com Positive 93.8%

Neg 0% Neu 0% Pos 93.8%

Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform.

Comments

No comments yet. Be the first!